Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-08-14 5:32 pm Purchase | 2025-06-30 | 13G | BioMarin Pharmaceutical Inc. BMRN | VIKING GLOBAL INVESTORS LP | 12,288,611 6.400% | 2,535,318 (+25.99%) | Filing History |
| 2025-08-14 12:43 pm Sale | 2025-06-30 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO/CA/ | 15,795,383 8.240% | -2,618,991 (-14.22%) | Filing History |
| 2025-05-13 11:32 am Sale | 2025-03-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 9,150,655 4.800% | -3,841,117 (-29.57%) | Filing History |
| 2025-04-29 09:14 am Sale | 2025-03-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | BlackRock Inc. BLK | 20,620,179 10.800% | -2,159,565 (-9.48%) | Filing History |
| 2025-02-13 2:14 pm Purchase | 2024-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 12,991,772 6.800% | 2,217,131 (+20.58%) | Filing History |
| 2024-09-30 4:29 pm Purchase | 2024-09-20 | 13G | BioMarin Pharmaceutical Inc. BMRN | VIKING GLOBAL INVESTORS LP | 9,753,293 5.100% | 9,753,293 (New Position) | Filing History |
| 2024-07-10 1:14 pm Purchase | 2024-06-28 | 13G | BioMarin Pharmaceutical Inc. BMRN | The Vanguard Group | 18,992,533 10.000% | 943,976 (+5.23%) | Filing History |
| 2024-07-08 4:32 pm Purchase | 2024-06-30 | 13G | BioMarin Pharmaceutical Inc. BMRN | BlackRock Inc. BLK | 22,779,744 12.000% | 8,038,908 (+54.53%) | Filing History |
| 2024-02-13 5:01 pm Purchase | 2023-12-29 | 13G | BioMarin Pharmaceutical Inc. BMRN | The Vanguard Group | 18,048,557 9.580% | 683,477 (+3.94%) | Filing History |
| 2024-02-13 1:21 pm Sale | 2023-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | Dodge & Cox | 13,994,063 7.400% | -389,600 (-2.71%) | Filing History |
| 2024-02-12 4:01 pm Purchase | 2023-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO/CA/ | 18,414,374 9.780% | 833,515 (+4.74%) | Filing History |
| 2024-02-09 5:46 pm Purchase | 2024-02-07 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 10,774,641 5.700% | 5,123,640 (+90.67%) | Filing History |
| 2024-01-26 11:49 am Sale | 2023-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | BlackRock Inc. BLK | 14,740,836 7.800% | -465,854 (-3.06%) | Filing History |
| 2023-02-14 1:25 pm Sale | 2022-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | Dodge & Cox | 14,383,663 7.700% | -441,386 (-2.98%) | Filing History |
| 2023-02-13 3:32 pm Sale | 2023-02-14 | 13G | BioMarin Pharmaceutical Inc. BMRN | Capital Research Global Investors | 5,651,001 3.000% | -7,021,007 (-55.41%) | Filing History |
| 2023-02-09 4:01 pm Sale | 2022-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | PRIMECAP MANAGEMENT CO/CA/ | 17,580,859 9.460% | -223,921 (-1.26%) | Filing History |
| 2023-02-09 11:12 am Purchase | 2022-12-30 | 13G | BioMarin Pharmaceutical Inc. BMRN | The Vanguard Group | 17,365,080 9.340% | 1,014,049 (+6.20%) | Filing History |
| 2023-02-03 4:27 pm Purchase | 2022-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | BlackRock Inc. BLK | 15,206,690 8.200% | 1,185,398 (+8.45%) | Filing History |
| 2022-03-11 2:13 pm Unchanged | 2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | BlackRock Inc. BLK | 14,021,292 7.600% | 0 (Unchanged) | Filing History |
| 2022-02-14 12:48 pm Purchase | 2021-12-31 | 13G | BioMarin Pharmaceutical Inc. BMRN | Dodge & Cox | 14,825,049 8.100% | 5,028,125 (+51.32%) | Filing History |